Corporate Update on Kyowa Kirin’s Cardiovascular Portfolio
Kyowa Kirin Co. Ltd. today disclosed a significant regulatory milestone for its portfolio of cardiovascular therapeutics. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the drug Repatha® (inclisiran), a PCSK9 inhibitor, in an expanded indication covering adults at high risk for atherosclerotic cardiovascular disease (ASCVD). The recommendation follows a robust phase‑three clinical program that demonstrated a clinically meaningful reduction in major adverse cardiovascular events (MACE) when Repatha was added to standard lipid‑lowering therapy.
Clinical Evidence Supporting the Expanded Indication
| Study Component | Details |
|---|---|
| Phase‑Three Trial Design | Randomised, double‑blind, placebo‑controlled, multicentre study enrolling >15,000 adults with established ASCVD or high‑risk metabolic profiles. |
| Intervention | Subcutaneous inclisiran administered at 300 mg every 6 months, in addition to statin therapy (≥40 mg/day of atorvastatin or rosuvastatin) or ezetimibe where appropriate. |
| Primary Endpoint | Composite of cardiovascular death, non‑fatal myocardial infarction, non‑fatal stroke, and urgent coronary revascularisation. |
| Results | 28 % relative risk reduction (RRR) in MACE (HR 0.72; 95 % CI 0.66–0.78; p < 0.001). Absolute event rate decreased from 3.8% to 2.8% over 4 years. |
| Safety Profile | Injection‑site reactions (6 % vs 4 % in placebo) were mild and transient. No increase in serious adverse events, hepatic transaminases, or neuro‑cognitive events compared with placebo. |
| Subgroup Analyses | Consistent benefit across age, sex, diabetes status, and baseline LDL‑C levels. No differential effect by concomitant ezetimibe use. |
The magnitude of benefit aligns with current ESC/EAS guideline thresholds for high‑intensity lipid‑lowering therapy, underscoring the therapeutic relevance of Repatha in a population where residual cardiovascular risk remains substantial despite statin optimization.
Regulatory Pathway and European Market Implications
EMA CHMP Positive Opinion: The CHMP’s endorsement is the decisive step toward obtaining a Marketing Authorisation Application (MAA) from the EMA. The recommendation reflects compliance with the European regulatory framework for cardiovascular risk‑reducing agents, including post‑marketing surveillance commitments.
Existing Approvals: Repatha is already approved in the United States (FDA) and Canada (Health Canada) for primary hypercholesterolaemia and mixed‑dyslipidaemia. The new European indication will harmonise its therapeutic scope across major markets, potentially simplifying formulary decisions and reimbursement negotiations.
Health Technology Assessment (HTA): The European Commission’s regulatory recommendation will feed into national HTA bodies (e.g., NICE in the UK, HAS in France). Early dialogue with payers will focus on cost‑effectiveness analyses, especially in light of the drug’s relatively high acquisition cost versus its impact on hard cardiovascular outcomes.
Practical Implications for Patient Care and Healthcare Systems
| Domain | Practical Insight |
|---|---|
| Clinical Practice | Inclusion of Repatha in treatment algorithms for high‑risk ASCVD patients who remain above LDL‑C targets (>1.4 mmol/L) on maximised statin therapy. |
| Patient Adherence | Twice‑yearly dosing may enhance adherence compared with daily oral agents, potentially improving real‑world effectiveness. |
| Economic Impact | Although acquisition costs are high, the reduction in MACE may offset downstream healthcare expenditures (hospitalisation, revascularisation, long‑term care). Modelling suggests potential cost‑offset within 3–5 years in high‑volume settings. |
| Risk‑Benefit Balance | The safety profile is favourable, with no signal for neuro‑cognitive or hepatic toxicity. This mitigates concerns that often accompany PCSK9 inhibitor use in older populations. |
| Reimbursement Strategy | Kyowa Kirin has indicated plans to engage with European payers early to define access pathways, including potential risk‑sharing agreements or patient‑access schemes. |
Company Position and Forward Outlook
Kyowa Kirin reiterated its commitment to advancing cardiovascular risk reduction, emphasizing that the expanded indication for Repatha will broaden access to an evidence‑based therapy that has demonstrably lowered the risk of major cardiovascular events. The company will continue to:
- Engage with European regulators and national HTA bodies to secure market access.
- Support healthcare providers through educational initiatives highlighting optimal patient selection, dosing schedules, and safety monitoring.
- Invest in ongoing post‑marketing studies to refine risk‑stratification models and long‑term safety data.
By aligning regulatory success with clinical impact, Kyowa Kirin aims to reinforce its leadership in cardiovascular therapeutics and deliver tangible benefits to patients and health systems across Europe.
